Brief: Beam Therapeutics Announces First Patient Dosed In Phase 1/2 Trial Of BEAM-201 In Relapsed, Refractory T-ALL/T-LL
05/09/2023 11:41
Sept 5 (Reuters) - Beam Therapeutics Inc BEAM.O :
* BEAM THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
1/2
TRIAL OF BEAM-201 IN RELAPSED, REFRACTORY T-ALL/T-LL
Source text for Eikon: ID:nGNX2VL37Q
Further company coverage: BEAM.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Beam Therapeutics
See all newsBeam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta